SCTV01C
Sponsors
Sinocelltech Ltd.
Conditions
COVID-19SARS-CoV-2 InfectionSARS-CoV2 Infection
Phase 1
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.
NCT05043311
Start: 2021-12-22End: 2023-01-01Target: 300Updated: 2022-01-25
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.
NCT05043285
Start: 2021-12-22End: 2023-01-01Target: 300Updated: 2022-01-25
The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults
CompletedNCT05148091
Start: 2021-12-01End: 2023-08-04Updated: 2024-02-08
Phase 2
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine
NCT05238454
Start: 2022-03-20End: 2022-12-01Target: 600Updated: 2022-03-02
A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine
WithdrawnNCT05239975
Start: 2022-04-25End: 2023-02-01Updated: 2024-02-09
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
NCT05239806
Start: 2022-04-01End: 2023-08-01Target: 400Updated: 2022-04-11
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
WithdrawnNCT05308602
Start: 2022-04-01End: 2023-08-01Updated: 2024-02-09